Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Emmanuel Papadakis

Interventional Cardiology Redding, CA Medical Doctor

NPI 1710077698 CMS profile 31910

2175 Rosaline Ave, Redding, CA 96001

Open in the dashboard

General payments

$13,307

426 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emmanuel Papadakis of Redding, CA is reported in the CMS Open Payments database as having received $13,307 across 426 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,014 79
2024 General $1,316 41
2023 General $1,545 57
2022 General $5,689 101
2021 General $1,570 58
2020 General $919 53
2019 General $1,255 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emmanuel Papadakis
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Emmanuel Papadakis were reported at $1,014. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Emmanuel Papadakis Interventional Cardiology median Middle half National median
2019 $1,255 $1,097 $329–$3,048 $163
2020 $919 $473 $161–$1,480 $114
2021 $1,570 $677 $233–$1,827 $132
2022 $5,689 $978 $333–$2,724 $149
2023 $1,545 $1,136 $382–$2,986 $160
2024 $1,316 $1,181 $395–$3,326 $164
2025 $1,014 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $5,917 204 payments
  2. Medtronic, Inc. $4,266 154 payments
  3. W. L. Gore & Associates, Inc. $1,462 8 payments
  4. Medtronic Vascular, Inc. $734 32 payments
  5. Abiomed $270 5 payments
  6. Philips Electronics North America Corporation $129 2 payments
  7. Biosense Webster, Inc. $125 5 payments
  8. TerSera Therapeutics LLC $109 1 payment
  9. Shockwave Medical, Inc $103 6 payments
  10. Boston Scientific Corporation $70 1 payment
  11. Other $124 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,457 403 payments
  2. Travel and Lodging $2,836 22 payments
  3. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. Micra $3,221 71 payments
  2. GORE CARDIOFORM Septal Occluder $1,462 8 payments
  3. Quadra Assura CRT Defibrillator Cardiac Arrhythmias and Heart Failure $899 19 payments
  4. AVEIR Cardiac Rhythm Management $842 20 payments
  5. Quadra Assura CRT Defibrillator Cardiac Rhythm Management $697 13 payments
  6. GALLANT $648 22 payments
  7. AVEIR Cardiac Rhythm Management $543 8 payments
  8. Claria MRI $482 15 payments
  9. COBALT DR MRI SURESCAN $299 28 payments
  10. Fortify Assura, Ellipse ICD $292 9 payments
  11. Other $3,908 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

166

Median for Cardiology: 2,533

Drug cost

$916

Median for Cardiology: $485,213

Branded share of claims

25.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 43 $354
Atorvastatin Calcium Generic 31 $225
Carvedilol Generic 29 $165
Spironolactone Generic 27 $82
Metoprolol Succinate Generic 13 $49
Lisinopril Generic 23 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$141,576

Medicare's payments for the services billed

Medicare patients

751

Average age 75

Services billed

1,324

375 women, 376 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 57%
Ischemic heart disease 55%
Arthritis 49%
Atrial fibrillation 46%
Diabetes 44%
Chronic kidney disease 44%
COPD 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

426 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record